This study tested the hypothesis that metoprolol reduces the restenosis rate after percutaneous transluminal coronary angioplasty (PTCA) in native coronary arteries as compared to placebo. Apart from prognostic clinical effects in the treatment of patients with coronary heart disease, several in vivo and ex vivo studies have demonstrated antiproliferative and antiatherogenic effects of beta-blockers. In the present study, 192 male patients were randomized in a double-blind fashion to metoprolol sustained-release treatment or placebo starting at least 1 day before angioplasty. Lesion diameters and restenosis rates were evaluated using automatic edge detection systems. The study endpoint was the angiographic restenosis rate 4 months after PTCA. Ninety-seven randomized patients had a control angiography a mean of 4.5 months after PTCA. Dropouts were evenly distributed between the metoprolol and placebo groups. Lumen loss in the target lesion was 0.36 mm in the metoprolol group and 0.32 mm in the placebo group. Restenosis rates averaged 57.5% in the metoprolol group and 44.2% in the placebo group using conventional restenosis criteria. Taking metoprolol serum levels above 50 mmol/l as an indication of definite compliance with the metoprolol treatment, the restenosis rate was 58.3%. In conclusion, 95 mg of sustained-release metoprolol failed to reduce the restenosis rate following angioplasty in native coronary arteries.

Keywords:
Restenosis, Beta-blockers, Metoprolol
1.
Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Gianbartolomei A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AJ, O’Neill WW, Morice MC: Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999;341:1949–1956.
2.
Erbel R, Haude M, Höpp HW, Franzen D, Rupprecht HJ, Heublein B, Fischer K, de Jaegere P, Serruys P, Rutsch W, Probst P: Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med 1998;339:1672–1678.
3.
Franzen D, Schannwell M, Oette K, Höpp HW: A prospective, randomized, and double-blind trial on the effect of fish oil on the incidence of restenosis following PTCA. Cathet Cardiovasc Diagn 1993;28:301–310.
4.
Jorgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, Hansen J, Webb J, Buller C, Goulet G, Erikssen J, Thaulow E: Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: Results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 2000;35:592–599.
5.
Feldman RL, MacDonald RG, Hill JA, Limacher MC, Conti R, Pepine CJ: Effect of propanolol on myocardial ischemia occurring during acute coronary occlusion. Circulation 1986;73:727–733.
6.
Ablad B, Björkman JA, Gustafsson D, Hansson G, Östlund-Lindqvist AM, Pettersson K: The role of sympathetic activity in atherogenesis: Effects of β-blockade. Am Heart J 1988;116:322–328.
7.
Johansson SR, Lamm C, Bondjers G, Emanuelsson H, Hjalmarson A: Role of beta-adrenergic blockers after percutaneous transluminal coronary angioplasty. Am J Cardiol 1990;66:915–920.
8.
Orekhov AN, Andrianova IV, Rekhter MD, Tertov VV, Andreeva ER, Ragimov SE, Mironov AA: Beta-blockers: Propanolol, metoprolol, atenolol, pindolol, alprenolol and timolol, manifest atherogenicity on in vitro, ex vivo and in vivo models. Elimination of propanolol atherogenic effects by papaverine. Atherosclerosis 1992;95:77–85.
9.
Vesselinovitch D, Mullan JF, Wissler RW, Davis HR, Bridenstine T: Carotid atherogenesis inhibited by sympathectomy, propanolol, and nifedipine in rhesus monkeys. Arteriosclerosis 1986;6:561a.
10.
Chobanian AV, Brecher P, Chan C: Effects of propanolol on atherogenesis in the cholesterol-fed rabbit. Circ Res 1985;56:755–762.
11.
Whittington-Coleman PJ, Carrier O Jr, Douglas BH: The effects of propanolol on cholesterol-induced atheromatous lesions. Atherosclerosis 1973;18:337–345.
12.
Östlund-Lindqvist AM, Lindqvist P, Bräutigam J, Olsson G, Bondjers G, Nordborg C: Effect of metoprolol on diet-induced atherosclerosis in rabbits. Atherosclerosis 1988;8:40–45.
13.
Kaplan JR, Manuck SB, Adams MR, Weingand KW, Clarkson TB: Inhibition of coronary atherosclerosis by propanolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation 1987;76:1364–1372.
14.
Balkin J, Rosenmann D, Ilan M, Zion MM: Reproducibility of measurements of coronary narrowings by videodensitometry and by digital calipers. Cardiology 1992;81:238–244.
15.
Beatt KJ, Serruys PW, Hugenholtz PG: Restenosis after coronary angioplasty: New standards for clinical studies. J Am Coll Cardiol 1990;15:491–498.
16.
Arora RR, Konrad K, Badhwar K, Hollman J: Restenosis after transluminal coronary angioplasty: A risk factor analysis. Cathet Cardiovasc Diagn 1990;19:17–22.
17.
Faxon DP: Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 1995;2:362–369.
18.
Verin V, Urban P, Popowski Y, Schwager M, Nouet P, Dorsaz PA, Chatelain P, Kurtz JM, Rutishauser W: Feasibility of intracoronary beta-irradiation to reduce restenosis after balloon angioplasty. A clinical pilot study. Circulation 1997;95:1138–1144.
19.
Muller DW, Topol E, Abrams GD, Gallagher KP, Ellis SG: Intramural methotrexate therapy for the prevention of neointimal thickening after balloon angioplasty. J Am Coll Cardiol 1992;20:460–464.
20.
Kuntz RE, Safian RD, Carrozza JP, Fishman RF, Mansour M, Baim DS: The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting. Circulation 1992;86:1827–1835.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.